Evaluating the Effects of Treatment Conversion for Huntington’s Chorea
Overnight treatment conversion from tetrabenazine to deutetrabenazine in patients with HD was found to be safe.
Overnight treatment conversion from tetrabenazine to deutetrabenazine in patients with HD was found to be safe.
Valbenazine is the first drug approved for the treatment of tardive dyskinesia, an adverse effect associated with the use of some antipsychotic medications.
Deutetrabenazine is only the second drug approved for patients with Huntington’s disease.